NR 566 Advanced Pharmacology
Final Examination
Chamberlain University | 2026
250 Questions with Expert Rationales
Instructions
• This examination consists of 250 multiple-choice questions.
• Select the single best answer for each question.
• Rationales are provided to explain the clinical reasoning, mechanism of action, and
evidence-based guidelines supporting each answer.
Section 1: Pharmacokinetics, Pharmacodynamics, and
Foundational Principles (Questions 1-25)
1. A 78-year-old patient with heart failure and hypoalbuminemia is prescribed
digoxin. The NP anticipates which pharmacokinetic change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
fraction of free (active) digoxin. Combined with age-related renal decline, this
significantly increases toxicity risk.
,2. A drug has a half-life of 36 hours. Approximately how many days will it take
to reach steady state?
A. 2-3 days
B. 5-7 days
C. 7-10 days
D. 10-14 days
Answer: C
Expert Rationale: Steady state is achieved after 4-5 half-lives. With a 36-hour
half-life, steady state occurs in approximately 7-10 days.
3. Which statement best describes a non-competitive antagonist?
A. It binds reversibly to the same receptor site as the agonist.
B. It binds irreversibly to the receptor or allosterically, reducing the maximal
response.
C. It produces the same maximal response as the agonist.
D. It enhances the effect of the agonist.
Answer: B
Expert Rationale: A non-competitive antagonist binds irreversibly or
allosterically, reducing the maximal response (efficacy) of the agonist. It cannot be
overcome by increasing agonist concentration.
4. A patient is a CYP2C19 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Clopidogrel
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Clopidogrel is a prodrug requiring CYP2C19-mediated
activation. Poor metabolizers have reduced conversion to the active metabolite,
increasing risk of thrombotic events.
5. The NP prescribes a medication with high first-pass metabolism. Which route
would achieve the highest bioavailability?
A. Oral
B. Sublingual
C. Intravenous
D. Subcutaneous
Answer: C
Expert Rationale: Intravenous administration delivers the drug directly into
,systemic circulation, completely bypassing first-pass metabolism and achieving 100%
bioavailability.
6. A patient with an eGFR of 20 mL/min requires a medication that is 90%
renally excreted. What is the most appropriate adjustment?
A. Increase the dose
B. Decrease the dose and/or prolong the dosing interval
C. No adjustment needed
D. Administer with a high-fat meal
Answer: B
Expert Rationale: Renally excreted drugs accumulate in renal impairment. Dose
reduction or interval prolongation is required to prevent toxicity.
7. Which genetic variation is associated with an increased risk of abacavir
hypersensitivity reaction?
A. HLA-B*5701
B. HLA-B*5801
C. CYP2C9*2
D. VKORC1
Answer: A
Expert Rationale: HLA-B*5701 screening is required before abacavir initiation.
Patients positive for this allele are at high risk for hypersensitivity and should not
receive abacavir.
8. A patient develops Stevens-Johnson syndrome after starting lamotrigine.
This is classified as which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Answer: B
Expert Rationale: Stevens-Johnson syndrome is a Type B (idiosyncratic) reaction
that is unpredictable, not dose-related, and often immune-mediated.
9. A drug that is a P-glycoprotein (P-gp) substrate is administered orally. What
effect would a P-gp inhibitor have on this drug?
A. Decreased absorption
B. Increased absorption and increased drug levels
C. No effect
D. Increased metabolism
, Answer: B
Expert Rationale: P-gp pumps drugs back into the intestinal lumen. Inhibiting P-
gp increases absorption and bioavailability, potentially leading to increased drug
levels and toxicity.
10. Which drug property most facilitates penetration across the blood-brain
barrier?
A. High polarity
B. High lipophilicity and low molecular weight
C. High protein binding
D. High water solubility
Answer: B
Expert Rationale: Lipophilic, non-polar, low molecular weight drugs can diffuse
across the lipid bilayer of the blood-brain barrier more readily than hydrophilic or
large molecules.
11. A patient is started on a medication that is a strong CYP3A4 inhibitor. The
NP anticipates that levels of CYP3A4 substrates will:
A. Decrease
B. Increase
C. Remain unchanged
D. Fluctuate unpredictably
Answer: B
Expert Rationale: CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit
juice) decrease metabolism of CYP3A4 substrates, leading to increased drug levels
and potential toxicity.
12. Which physiologic change in older adults most significantly affects drug
absorption?
A. Decreased gastric acid secretion
B. Increased gastric emptying
C. Increased intestinal blood flow
D. Decreased intestinal surface area
Answer: A
Expert Rationale: Age-related decrease in gastric acid secretion can affect the
absorption of drugs that require an acidic environment (e.g., ketoconazole, iron) and
may alter the dissolution of some formulations.
13. A weak base with a pKa of 8.5 will be mostly non-ionized and well-absorbed
in which environment?
A. Stomach (pH 1.5)
Final Examination
Chamberlain University | 2026
250 Questions with Expert Rationales
Instructions
• This examination consists of 250 multiple-choice questions.
• Select the single best answer for each question.
• Rationales are provided to explain the clinical reasoning, mechanism of action, and
evidence-based guidelines supporting each answer.
Section 1: Pharmacokinetics, Pharmacodynamics, and
Foundational Principles (Questions 1-25)
1. A 78-year-old patient with heart failure and hypoalbuminemia is prescribed
digoxin. The NP anticipates which pharmacokinetic change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
fraction of free (active) digoxin. Combined with age-related renal decline, this
significantly increases toxicity risk.
,2. A drug has a half-life of 36 hours. Approximately how many days will it take
to reach steady state?
A. 2-3 days
B. 5-7 days
C. 7-10 days
D. 10-14 days
Answer: C
Expert Rationale: Steady state is achieved after 4-5 half-lives. With a 36-hour
half-life, steady state occurs in approximately 7-10 days.
3. Which statement best describes a non-competitive antagonist?
A. It binds reversibly to the same receptor site as the agonist.
B. It binds irreversibly to the receptor or allosterically, reducing the maximal
response.
C. It produces the same maximal response as the agonist.
D. It enhances the effect of the agonist.
Answer: B
Expert Rationale: A non-competitive antagonist binds irreversibly or
allosterically, reducing the maximal response (efficacy) of the agonist. It cannot be
overcome by increasing agonist concentration.
4. A patient is a CYP2C19 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Clopidogrel
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Clopidogrel is a prodrug requiring CYP2C19-mediated
activation. Poor metabolizers have reduced conversion to the active metabolite,
increasing risk of thrombotic events.
5. The NP prescribes a medication with high first-pass metabolism. Which route
would achieve the highest bioavailability?
A. Oral
B. Sublingual
C. Intravenous
D. Subcutaneous
Answer: C
Expert Rationale: Intravenous administration delivers the drug directly into
,systemic circulation, completely bypassing first-pass metabolism and achieving 100%
bioavailability.
6. A patient with an eGFR of 20 mL/min requires a medication that is 90%
renally excreted. What is the most appropriate adjustment?
A. Increase the dose
B. Decrease the dose and/or prolong the dosing interval
C. No adjustment needed
D. Administer with a high-fat meal
Answer: B
Expert Rationale: Renally excreted drugs accumulate in renal impairment. Dose
reduction or interval prolongation is required to prevent toxicity.
7. Which genetic variation is associated with an increased risk of abacavir
hypersensitivity reaction?
A. HLA-B*5701
B. HLA-B*5801
C. CYP2C9*2
D. VKORC1
Answer: A
Expert Rationale: HLA-B*5701 screening is required before abacavir initiation.
Patients positive for this allele are at high risk for hypersensitivity and should not
receive abacavir.
8. A patient develops Stevens-Johnson syndrome after starting lamotrigine.
This is classified as which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre)
C. Type C (chronic)
D. Type D (delayed)
Answer: B
Expert Rationale: Stevens-Johnson syndrome is a Type B (idiosyncratic) reaction
that is unpredictable, not dose-related, and often immune-mediated.
9. A drug that is a P-glycoprotein (P-gp) substrate is administered orally. What
effect would a P-gp inhibitor have on this drug?
A. Decreased absorption
B. Increased absorption and increased drug levels
C. No effect
D. Increased metabolism
, Answer: B
Expert Rationale: P-gp pumps drugs back into the intestinal lumen. Inhibiting P-
gp increases absorption and bioavailability, potentially leading to increased drug
levels and toxicity.
10. Which drug property most facilitates penetration across the blood-brain
barrier?
A. High polarity
B. High lipophilicity and low molecular weight
C. High protein binding
D. High water solubility
Answer: B
Expert Rationale: Lipophilic, non-polar, low molecular weight drugs can diffuse
across the lipid bilayer of the blood-brain barrier more readily than hydrophilic or
large molecules.
11. A patient is started on a medication that is a strong CYP3A4 inhibitor. The
NP anticipates that levels of CYP3A4 substrates will:
A. Decrease
B. Increase
C. Remain unchanged
D. Fluctuate unpredictably
Answer: B
Expert Rationale: CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit
juice) decrease metabolism of CYP3A4 substrates, leading to increased drug levels
and potential toxicity.
12. Which physiologic change in older adults most significantly affects drug
absorption?
A. Decreased gastric acid secretion
B. Increased gastric emptying
C. Increased intestinal blood flow
D. Decreased intestinal surface area
Answer: A
Expert Rationale: Age-related decrease in gastric acid secretion can affect the
absorption of drugs that require an acidic environment (e.g., ketoconazole, iron) and
may alter the dissolution of some formulations.
13. A weak base with a pKa of 8.5 will be mostly non-ionized and well-absorbed
in which environment?
A. Stomach (pH 1.5)
